Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02642315 · ClinicalTrials.gov registry record · NA
The Effect of Horizant (Gabapentin Enacarbil) on Augmentation
A NA study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02642315 is a NA study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 10 participants.
The verdict
NCT02642315, a NA study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Restless Legs Syndrome (RLS) is a common neurological disorder. Augmentation is the main complication during long-term DA treatment of RLS. This study aims to examine effect of Horizant (Gabapentin Enacarbil) on Augmentation in RLS patients.
Interventions
- DRUG Horizant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-05-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02642315
The ClinicalTrials.gov registry entry for NCT02642315 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Horizant is the first listed.
NCT02642315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02642315 about?
NCT02642315 is a clinical study titled "The Effect of Horizant (Gabapentin Enacarbil) on Augmentation". Restless Legs Syndrome (RLS) is a common neurological disorder. Augmentation is the main complication during long-term DA treatment of RLS. This study aims to examine effect of Horizant (Gabapentin Enacarbil) on Augmentation in RLS patients.
What is the current status of trial NCT02642315?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2016-01. Estimated completion is 2019-05-06.
What interventions are being tested in trial NCT02642315?
The interventions under investigation include: Horizant (DRUG).
Who is sponsoring clinical trial NCT02642315?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.